Gyre Therapeutics (GYRE) Tax Provisions (2010 - 2026)
Gyre Therapeutics (GYRE) reported Tax Provisions of $621000.0 for Q1 2026, down 31.08% year-over-year from $901000.0 in Q1 2025, and down 52.23% on a QoQ basis from $1.3 million in Q4 2025.
Gyre Therapeutics (GYRE) has 8 years of Tax Provisions data on file, last reported at $621000.0 in Q1 2026.
- Quarterly Tax Provisions fell 31.08% year-over-year to $621000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 16.35% YoY) and the FY2025 annual result came in at $4.6 million, down 14.36% from the prior year.
- Tax Provisions fell to $621000.0 in Q1 2026 per GYRE's latest filing, from $1.3 million in the prior quarter.
- Across five years, Tax Provisions topped out at $5.1 million in Q4 2022 and bottomed at $203000.0 in Q4 2024.
- The 5-year median for Tax Provisions is $1.4 million (2024), against an average of $1.7 million.
- The widest annual swing landed in 2023, when Tax Provisions slumped 86.29%; it then surged 540.39% in 2025.
- Tracing GYRE's Tax Provisions over 5 years: stood at $5.1 million in 2022, then tumbled by 86.29% to $699000.0 in 2023, then slumped by 70.96% to $203000.0 in 2024, then surged by 540.39% to $1.3 million in 2025, then slumped by 52.23% to $621000.0 in 2026.
- Per Business Quant, the three latest GYRE Tax Provisions figures stand at $621000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 621,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 621,000.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 901,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 699,000.00 |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 5.10 Mn |
| Mar 31, 2015 | 21,000.00 |
| Dec 31, 2014 | -56,000.00 |
| Sep 30, 2014 | 11,000.00 |
| Jun 30, 2014 | 45,000.00 |
| Mar 31, 2014 | 3.41 Mn |
| Dec 31, 2010 | 1.13 Mn |
| Sep 30, 2010 | 257,000.00 |
| Jun 30, 2010 | 1.51 Mn |